Posted by Merck / MSD has released an announcement on 13 June, 2023 that the U.S. District Court for the District of New Jersey ruled in favor of the company and found that Merck correctly calculated the Patent Term Extension period for the primary patent related to BRIDION® (sugammadex). Patent Term Extension is designed to restore some of the patent life lost during the regulatory review process for new drugs.
Today’s ruling from the U.S. District Court for the District of New Jersey affirms and validates Merck’s U.S. patent protection for BRIDION through at least January 2026.